Investor’s Toolkit: Key Ratios for Assessing Hims & Hers Health Inc (HIMS)’s Performance

Kevin Freeman

For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

Hims & Hers Health Inc (NYSE: HIMS) closed the day trading at $37.77 down -0.29% from the previous closing price of $37.88. In other words, the price has decreased by -$0.29 from its previous closing price. On the day, 10.02 million shares were traded. HIMS stock price reached its highest trading level at $37.86 during the session, while it also had its lowest trading level at $36.6501.

Ratios:

For a better understanding of HIMS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 74.07. For the most recent quarter (mrq), Quick Ratio is recorded 1.64 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.92.

Upgrades & Downgrades

In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $48.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’25 when Perez Garcia Andrea G sold 2,500 shares for $39.17 per share. The transaction valued at 97,925 led to the insider holds 80,166 shares of the business.

Perez Garcia Andrea G bought 2,500 shares of HIMS for $97,925 on Dec 09 ’25. On Nov 24 ’25, another insider, Boughton Soleil, who serves as the Chief Legal Officer of the company, sold 2,631 shares for $35.22 each. As a result, the insider received 92,664 and left with 153,225 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 8598284288 and an Enterprise Value of 9086563328. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 69.83, and their Forward P/E ratio for the next fiscal year is 63.13. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.89 while its Price-to-Book (P/B) ratio in mrq is 14.79. Its current Enterprise Value per Revenue stands at 4.11 whereas that against EBITDA is 53.925.

Stock Price History:

The Beta on a monthly basis for HIMS is 2.35, which has changed by 0.2581612 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $23.97. The 50-Day Moving Average of the stock is -15.35%, while the 200-Day Moving Average is calculated to be -17.73%.

Shares Statistics:

Over the past 3-months, HIMS traded about 26.68M shares per day on average, while over the past 10 days, HIMS traded about 14179390 shares per day. A total of 219.12M shares are outstanding, with a floating share count of 204.67M. Insiders hold about 10.09% of the company’s shares, while institutions hold 89.50% stake in the company. Shares short for HIMS as of 1764288000 were 67327436 with a Short Ratio of 2.52, compared to 1761868800 on 70158018. Therefore, it implies a Short% of Shares Outstanding of 67327436 and a Short% of Float of 36.580002.

Earnings Estimates

Current recommendations for the stock of the company come from 11.0 analysts. The consensus estimate for the next quarter is $0.15, with high estimates of $0.3 and low estimates of $0.1.

Analysts are recommending an EPS of between $0.58 and $0.38 for the fiscal current year, implying an average EPS of $0.48. EPS for the following year is $0.66, with 11.0 analysts recommending between $1.37 and $0.33.

Revenue Estimates

12 analysts predict $617.48M in revenue for. The current quarter. It ranges from a high estimate of $624.72M to a low estimate of $608.22M. As of. The current estimate, Hims & Hers Health Inc’s year-ago sales were $481.14MFor the next quarter, 12 analysts are estimating revenue of $658.67M. There is a high estimate of $673.8M for the next quarter, whereas the lowest estimate is $630.7M.

A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.35B, while the lowest revenue estimate was $2.33B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.77B in the next fiscal year. The high estimate is $2.94B and the low estimate is $2.52B.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.